A single rapamycin dose protects against late-stage experimental cerebral malaria via modulation of host immunity, endothelial activation and parasite sequestration

Maladaptive immune responses during cerebral malaria (CM) result in high mortality despite opportune anti-malarial chemotherapy. Rapamycin, an FDA-approved immunomodulator, protects against experimental cerebr...

Source: Malaria Journal - November 9, 2017 Category: Infectious Diseases Authors: Pedro Mejia, J. Humberto Trevi ño-Villarreal, Justin S. Reynolds, Mariana De Niz, Andrew Thompson, Matthias Marti and James R. Mitchell Tags: Research Source Type: research